Lidoderm
ApprovedSmall molecule
Endo PharmaceuticalsLidoderm is one of 170 small molecule programs targeting Low back pain. It is currently in Approved.
5
Indications
11
Total Trials
0
Active Trials
169
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lidoderm
Endo PharmaceuticalsApproved
Tykerb
GSKPreclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Voltaren
NovartisPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Tricor
JJagotec
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Low back pain4 trials
Show 1 more trial
Osteoarthritis3 trials
Postherpetic Neuralgia1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lidoderm. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company